Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Advanced Melanoma
Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the survival rate after 1 year of treatment with
ipilimumab plus dacarbazine in patients with previously untreated Stage III (unresectable) or
Stage IV melanoma.